市場調查報告書
商品編碼
1190545
牙科生物材料市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)Dental Biomaterials Market - Growth, Trends, and Forecasts (2023 - 2028) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2021 年牙科生物材料市場價值約為 64.6475 億美元,預計到 2027 年將達到 94.8713 億美元,在 2022-2027 年的預測期內以 6.77% 的複合年增長率增長。我來了。
COVID-19 大流行對市場的影響很大,包括牙科護理在內的一些選擇性手術在大流行期間暫停或推遲。 2020 年 3 月,美國牙科協會 (ADA) 將所有選擇性牙科護理推遲到 2020 年 4 月 6 日,以防止患者給醫院急診科帶來過多負擔,從而推遲僅提供緊急牙科服務。建議提供 該公告於 2020 年 4 月 1 日更新,ADA 建議由於 COVID-19 病例增加,除緊急和急救外,診所關閉至 4 月 30 日。 結果,獲得牙科保健的機會大大減少。 而根據英國牙科協會公佈的數據,2020年7月,英國2053名牙醫中只有36%的人有條件恢復牙科執業。 在大流行的早期階段,牙科服務和治療的延遲減少了對牙科生物材料的需求,對市場增長產生了負面影響。 然而,隨著 COVID-19 的嚴重程度和感染率下降,隨著全球選擇性牙科護理的恢復,市場正在獲得吸引力。
此外,推動市場增長的主要因素包括牙科疾病負擔的增加、牙科旅遊的擴張、種植牙普及率的提高以及新興國家可支配收入的增加。
牙科疾病負擔的增加和牙科旅遊的增加是推動市場增長的主要因素。 牙周病、蛀牙、口腔癌、口臭和齲齒等牙科疾病負擔的增加是市場增長的推動力。 例如,根據世界衛生組織(WHO)2020年3月的最新信息,口腔疾病估計影響全球約35億人,其中嚴重的牙周(牙齦)疾病尤為常見。。 還有一篇標題為“牙科旅遊 2021”的文章。 2021 年 12 月在 Dentaly.org 上發表的“在國外獲得更便宜的牙科植入物和貼面”指出,牙科植入物旅遊是一項受成本節約□□推動的不斷增長的業務。 預計這些因素將在未來幾年推動牙科生物材料的需求,從而增加患者對牙科手術的採用。
然而,監管問題和治療成本是限制市場增長的因素之一。
按類型劃分,金屬生物材料預計將顯著增長。 金屬生物材料是牙科中使用的一類主要材料。 這是由於與這些材料相關的高強度和其他機械性能。 這些生物材料由於鈦、鎵和矽等的承重和抗疲勞特性而被廣泛用於製造外科植入物。
在2021年11月發表的一篇題為“社論”的文章“Metallic Biomaterials for Medical Applications”中,與其他金屬植入材料相比,鈦合金具有優越的生物相容性、耐腐蝕性和比強度。因此,它被廣泛用作牙科材料和植入材料。 此外,根據 2020 年 8 月發表的論文“Review of Metallic Biomaterials in Dental Applications”,Ti-Ga-Si 將 Ti-Ga 合金的優點與 Si 相結合,為患者帶來了美觀的效果。據信可以增強骨整合,並具有最小的醫療並發症的可能性。
此類研究將對該細分市場的增長產生積極影響,因為它證明了金屬生物材料的有效性,並有望創造對金屬植入物的巨大需求。
在北美地區,美國有望實現顯著增長。 政府機構支持的產品發布增加、牙科疾病負擔增加以及老年人口不斷增加正在推動美國對牙科生物材料的需求。
例如,根據美國牙科協會的數據,到 2020 年,將有超過 500 萬年齡在 65 至 74 歲之間的美國人完全沒有牙齒,近 300 萬將患有無牙頜。 另一方面,掉牙主要是老年人的問題。 由於 91% 的 20-64 歲成年人有蛀牙,其中 27% 未接受治療。 此外,因蛀牙而導致牙齒脫落的案例也很多。 因此,預計這些因素將增加美國進行的牙科手術總數,從而增加國內對牙科生物材料的需求。
此外,一些市場參與者也參與實施戰略計劃,從而推動市場增長。 例如,2020 年 1 月,位於大波士頓地區的牙科研究和製造公司 Pulpdent Corporation 推出了 ACTIVA Presto 牙科材料。 這種新型白色牙科填充材料模仿了天然牙齒的特性。 此外,2021 年 4 月,高科技牙科材料和設備的開發商和製造商 Ultradent Products 將收購墨西哥牙科產品藍籌分銷商 Vamasa SA de CV 的多數股權。底部。
因此,考慮到上述因素,預計該市場在預測期內將出現顯著增長。
由於國內外參與者的存在,牙科生物材料市場競爭激烈。 大部分市場份額被全球玩家佔據,而中小企業則在新技術的幫助下展開激烈的競爭。 未來,隨著新進入者開發創新產品,市場份額有望在國際和小型企業之間實現多元化。 主要參與者包括 Straumann Holding AG、Dentsply Sirona Inc.、3M Company、ZimVie Inc. 和 Botiss Biomaterials GmbH。
The dental biomaterials market was valued at about USD 6,464.75 million in 2021, and it is expected to reach USD 9,487.13 million by 2027, recording a CAGR of 6.77% over the forecast period 2022-2027.
The impact of the COVID-19 pandemic on the market was significant as several elective procedures, including dental treatments, were halted or postponed during the pandemic. In March 2020, the American Dental Association (ADA) recommended postponing all elective dental procedures until April 6, 2020, and providing emergency-only dental services to keep patients from burdening hospital emergency departments. This recommendation was updated on April 1, 2020, when the ADA advised offices to remain closed except for urgent and emergency procedures until April 30, owing to the rise of COVID-19 cases. As a result, access to dental care substantially decreased. Also, as per data published by the British Dental Association, in July 2020, out of 2,053 dentists, only 36% were ready to resume dental practices in United Kingdom. During the initial phase of the pandemic, dental services and treatments were delayed, which resulted in decreased demand for dental biomaterials and affected market growth adversely. However, the market is gaining traction as elective dental procedures have resumed worldwide owing to the declining severity and infections of COVID-19.
Further, the major factors fueling the market growth include the rising burden of dental disorders, growing dental tourism, growing penetration of dental implants, and increasing disposable income across developing countries.
The rising burden of dental disorders and growing dental tourism are major factors driving the market growth. The growing burden of dental diseases such as periodontal disease, tooth decay, oral cancer, halitosis, and dental caries, among other diseases, is driving the market growth. For instance, as per a March 2020 update by the World Health Organization (WHO), it is estimated that oral diseases affect nearly 3.5 billion people globally, especially severe periodontal (gum) disease. Also, an article titled "Dental Tourism 2021: Get Cheaper Dental Implants and Veneers Abroad," published in Dentaly.org in December 2021, stated that dental implant tourism is a growing business attributed to cost savings. Such factors are thereby increasing the adoption of dental procedures among patients and are expected to drive the demand for dental biomaterials over the coming years.
Nevertheless, regulatory issues and the cost of procedures are some of the factors restraining the market growth.
By type, metallic biomaterials are expected to witness significant growth. Metallic biomaterials are a central class of materials for use in dental treatments. This can be attributed to the high strength and other mechanical properties associated with these materials. These biomaterials are extensively used to fabricate surgical implants owing to load-bearing characteristics and fatigue properties, such as titanium, gallium, and silicon.
As per an article published in November 2021, titled "Editorial: Metallic Biomaterials for Medical Applications," titanium alloys are widely used for dental and implant materials due to their superior biocompatibility, corrosion resistance, and specific strength compared with other metallic implant materials. In addition, as per an article titled, "Review of Metallic Biomaterials in Dental Applications," published in August 2020, Ti-Ga-Si is considered to combine the advantages of the Ti-Ga alloy along with Si, which enhances the osseointegration with aesthetically pleasing outcomes for patients and minimal likelihood of medical complications.
Such studies indicate the efficacy of metallic biomaterials and are expected to generate significant demand for metallic implants, thus positively impacting the segment's growth.
Within North America, United States is expected to observe significant growth. With the increase in product launches supported by government authorities, the rising burden of dental diseases and the increasing geriatric population are bolstering the demand for dental biomaterials in United States.
For instance, as per the American Dental Association, in 2020, more than 5 million US seniors aged 65 to 74 had complete tooth loss, with nearly 3 million suffering from edentulous. Tooth loss, on the other hand, is primarily a problem for the elderly. This is because 91% of adults aged 20 to 64 have dental caries, with a staggering 27% going untreated. Furthermore, tooth decay is a common cause of tooth loss in many cases. Thus, such factors are anticipated to boost the total dental procedures performed across United States, thereby boosting the demand for dental biomaterials within the country.
Furthermore, several market players are also engaged in implementing strategic initiatives, thereby propelling market growth. For instance, in January 2020, Pulpdent Corporation, a dental research and manufacturing company based in the Greater Boston area, launched its ACTIVA Presto dental material. The new white dental filling material mimics the properties of natural teeth. Moreover, in April 2021, Ultradent Products Inc., a developer and manufacturer of high-tech dental materials and equipment, purchased majority ownership in Vamasa SA de CV, a premier distributor of dental products in Mexico.
Thus, in view of the abovementioned factors, the market is expected to witness significant growth in the region over the forecast period.
The dental biomaterials market is moderately competitive, with the presence of local and international players in the market. The major share of the market has been grabbed by global players, whereas small to mid-sized companies are posing intense competition with the help of novel technologies. In the future, it is expected that the market share will be distributed among international players and small players as well due to the focus of new entrants to come up with innovative products. Some of the major players in the market are Straumann Holding AG, Dentsply Sirona Inc., 3M Company, ZimVie Inc., and Botiss Biomaterials GmbH.